|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malhotra GK, Yanala U, Ravipati A, Follet
M, Vijayakumar M and Are C: Global trends in esophageal cancer. J
Surg Oncol. 115:564–579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jha N, Harris J, Seikaly H, Jacobs JR,
McEwan AJ and Robbins KT: A phase II study of submandibular gland
transfer prior to radiation for prevention of radiation-induced
xerostomia in head-and-neck cancer (RTOG 0244). Int J Radiat Oncol
Biol Phys. 84:437–442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown JM: Tumor hypoxia in cancer therapy.
Methods Enzymol. 435:297–321. 2007.PubMed/NCBI
|
|
5
|
Hengstler JG, Bockamp EO, Hermes M,
Brulport M, Bauer A, Schormann W, Schiffer IB, Hausherr C, Eshkind
L, Antunes C, et al: Oncogene-blocking therapies: New insights from
conditional mouse tumor models. Curr Cancer Drug Targets.
6:603–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie
A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, et al:
Management of locally recurrent nasopharyngeal carcinoma. Cancer
Treat Rev. 79:1018902019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moeller BJ, Cao Y, Li CY and Dewhirst MW:
Radiation activates HIF-1 to regulate vascular radiosensitivity in
tumors: Role of reoxygenation, free radicals, and stress granules.
Cancer Cell. 5:429–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harada H, Itasaka S, Zhu Y, Zeng L, Xie X,
Morinibu A, Shinomiya K and Hiraoka M: Treatment regimen determines
whether an HIF-1 inhibitor enhances or inhibits the effect of
radiation therapy. Br J Cancer. 100:747–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwong LN, Zou L, Chagani S, Pedamallu CS,
Liu M, Jiang S, Protopopov A, Zhang J, Getz G and Chin L: Modeling
Genomic Instability and Selection Pressure in a Mouse Model of
Melanoma. Cell Rep. 19:1304–1312. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bussink J, van der Kogel AJ and Kaanders
JH: Activation of the PI3-K/AKT pathway and implications for
radioresistance mechanisms in head and neck cancer. Lancet Oncol.
9:288–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nijkamp MM, Hoogsteen IJ, Span PN, Takes
RP, Lok J, Rijken PF, van der Kogel AJ, Bussink J and Kaanders JH:
Spatial relationship of phosphorylated epidermal growth factor
receptor and activated AKT in head and neck squamous cell
carcinoma. Radiother Oncol. 101:165–170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harari PM and Huang SM: Combining EGFR
inhibitors with radiation or chemotherapy: Will preclinical studies
predict clinical results? Int J Radiat Oncol Biol Phys. 58:976–983.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Milas L, Fan Z, Andratschke NH and Ang KK:
Epidermal growth factor receptor and tumor response to radiation:
In vivo preclinical studies. Int J Radiat Oncol Biol Phys.
58:966–971. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giralt J, de las Heras M, Cerezo L, Eraso
A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majó J, et
al Grupo Español de Investigacion Clinica en Oncologia
Radioterápica (GICOR): The expression of epidermal growth factor
receptor results in a worse prognosis for patients with rectal
cancer treated with preoperative radiotherapy: A multicenter,
retrospective analysis. Radiother Oncol. 74:101–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baumann M, Krause M, Dikomey E, Dittmann
K, Dörr W, Kasten-Pisula U and Rodemann HP: EGFR-targeted
anti-cancer drugs in radiotherapy: Preclinical evaluation of
mechanisms. Radiother Oncol. 83:238–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang KL, Wu TT, Choi IS, Wang H, Resetkova
E and Correa AM: Expression of epidermal growth factor receptor in
esophageal and esophagogastric junction adenocarcinomas:
association with poor outcome. Cancer. 109:658–667. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diaz Miqueli A, Rolff J, Lemm M, Fichtner
I, Perez R and Montero E: Radiosensitisation of U87MG brain tumours
by anti-epidermal growth factor receptor monoclonal antibodies. Br
J Cancer. 100:950–958. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akashi Y, Okamoto I, Iwasa T, Yoshida T,
Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, et al:
Enhancement of the antitumor activity of ionising radiation by
nimotuzumab, a humanised monoclonal antibody to the epidermal
growth factor receptor, in non-small cell lung cancer cell lines of
differing epidermal growth factor receptor status. Br J Cancer.
98:749–755. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawaguchi Y, Kono K, Mimura K, Sugai H,
Akaike H and Fujii H: Cetuximab induce antibody-dependent cellular
cytotoxicity against EGFR-expressing esophageal squamous cell
carcinoma. Int J Cancer. 120:781–787. 2007. View Article : Google Scholar
|
|
20
|
Zhao L, Li QQ, Zhang R, Xi M, Liao YJ,
Qian D, He LR, Zeng YX, Xie D and Liu MZ: The overexpression of
IGFBP-3 is involved in the chemosensitivity of esophageal squamous
cell carcinoma cells to nimotuzumab combined with cisplatin. Tumour
Biol. 33:1115–1123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu Y, Li X, Xu H, Liu J, Dong M, Yang J,
Sun L, Sun X and Xing L: Correlation of hypoxia status with
radiosensitizing effects of sodium glycididazole: A preclinical
study. Oncol Lett. 15:6481–6488. 2018.PubMed/NCBI
|
|
22
|
Zips D, Eicheler W, Brüchner K, Jackisch
T, Geyer P, Petersen C, van der Kogel AJ and Baumann M: Impact of
the tumour bed effect on microenvironment, radiobiological hypoxia
and the outcome of fractionated radiotherapy of human FaDu
squamous-cell carcinoma growing in the nude mouse. Int J Radiat
Biol. 77:1185–1193. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen FH, Chiang CS, Wang CC, Fu SY, Tsai
CS, Jung SM, Wen CJ, Lee CC and Hong JH: Vasculatures in tumors
growing from preirradiated tissues: Formed by vasculogenesis and
resistant to radiation and antiangiogenic therapy. Int J Radiat
Oncol Biol Phys. 80:1512–1521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao L, He LR, Xi M, Cai MY, Shen JX, Li
QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, et al: Nimotuzumab promotes
radiosensitivity of EGFR-overexpression esophageal squamous cell
carcinoma cells by upregulating IGFBP-3. J Transl Med. 10:2492012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baraban E, Sadigh S, Rosenbaum J, Van
Arnam J, Bogusz AM, Mehr C and Bagg A: Cyclin D1 expression and
novel mutational findings in Rosai-Dorfman disease. Br J Haematol.
186:837–844. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okamoto I: Epidermal growth factor
receptor in relation to tumor development: EGFR-targeted anticancer
therapy. FEBS J. 277:309–315. 2010. View Article : Google Scholar
|
|
27
|
Li S, Kussie P and Ferguson KM: Structural
basis for EGF receptor inhibition by the therapeutic antibody
IMC-11F8. Structure. 16:216–227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chakravarti A, Winter K, Wu CL, Kaufman D,
Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, et
al: Expression of the epidermal growth factor receptor and Her-2
are predictors of favorable outcome and reduced complete response
rates, respectively, in patients with muscle-invading bladder
cancers treated by concurrent radiation and cisplatin-based
chemotherapy: A report from the Radiation Therapy Oncology Group.
Int J Radiat Oncol Biol Phys. 62:309–317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Crosby T, Hurt CN, Falk S, Gollins S,
Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI,
et al: Chemoradiotherapy with or without cetuximab in patients with
oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised
trial. Lancet Oncol. 14:627–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suntharalingam M, Winter K, Ilson D,
Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar
H, Horiba N, et al: Effect of the Addition of Cetuximab to
Paclitaxel, Cisplatin, and Radiation Therapy for Patients With
Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized
Clinical Trial. JAMA Oncol. 3:1520–1528. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu M, Wang X, Shen L, Jia J, Gong J, Li J,
Li J, Li Y, Zhang X, Lu Z, et al: Nimotuzumab plus paclitaxel and
cisplatin as the first line treatment for advanced esophageal
squamous cell cancer: A single centre prospective phase II trial.
Cancer Sci. 107:486–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramos-Suzarte M, Lorenzo-Luaces P, Lazo
NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ,
Moreno BP, Alvarez ES, et al: Treatment of malignant,
non-resectable, epithelial origin esophageal tumours with the
humanized anti-epidermal growth factor antibody nimotuzumab
combined with radiation therapy and chemotherapy. Cancer Biol Ther.
13:600–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Castro Junior G, Segalla JG, de Azevedo
SJ, Andrade CJ, Grabarz D, de Araújo Lima França B, Del Giglio A,
Lazaretti NS, Álvares MN, Pedrini JL, et al: A randomised phase II
study of chemoradiotherapy with or without nimotuzumab in locally
advanced oesophageal cancer: NICE trial. Eur J Cancer. 88:21–30.
2018. View Article : Google Scholar
|
|
34
|
Cheng JC, Klausen C and Leung PC:
Hypoxia-inducible factor 1 alpha mediates epidermal growth
factor-induced down-regulation of E-cadherin expression and cell
invasion in human ovarian cancer cells. Cancer Lett. 329:197–206.
2013. View Article : Google Scholar
|
|
35
|
Lin P, Wang W, Cai WJ, Han CR, Sun Y, Li M
and Sun BC: Relationship between the expression of
hypoxia-inducible factor-1alpha and epidermal growth factor
receptor and micro vessel density and their clinical significance.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 44:480–485. 2009.In
Chinese. PubMed/NCBI
|
|
36
|
Wouters A, Boeckx C, Vermorken JB, Van den
Weyngaert D, Peeters M and Lardon F: The intriguing interplay
between therapies targeting the epidermal growth factor receptor,
the hypoxic microenvironment and hypoxia-inducible factors. Curr
Pharm Des. 19:907–917. 2013. View Article : Google Scholar
|
|
37
|
Peng XH, Karna P, Cao Z, Jiang BH, Zhou M
and Yang L: Cross-talk between epidermal growth factor receptor and
hypoxia-inducible factor-1alpha signal pathways increases
resistance to apoptosis by up-regulating survivin gene expression.
J Biol Chem. 281:25903–25914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu P, Liu J, Sun X, Li X, Xing L and Yu J:
Enhanced radio-sensitizing by sodium glycididazole in a recurrent
esophageal carcinoma tumor model. Oncotarget. 8:63871–63880.
2017.PubMed/NCBI
|
